Patents by Inventor Jianwen A. Feng

Jianwen A. Feng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Kinase Inhibitors and Uses Thereof
    Publication number: 20220041620
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Application
    Filed: October 26, 2021
    Publication date: February 10, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R.H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Modulators of eukaryotic initiation factor 2B, compositions and methods
    Patent number: 11236100
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Grant
    Filed: August 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Denali Therapeutics Inc.
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R. H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • Compounds, Compositions and Methods
    Publication number: 20220024938
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: October 5, 2021
    Publication date: January 27, 2022
    Applicant: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Compound, compositions, and methods
    Patent number: 11214565
    Abstract: Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: January 4, 2022
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Kinase inhibitors and uses thereof
    Patent number: 11203600
    Abstract: The present disclosure relates generally to compounds and compositions, intermediates, processes for their preparation, and their use as kinase inhibitors.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: December 21, 2021
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier De Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Christopher R. H. Hale, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Elena Serra, Zachary K. Sweeney, Arun Thottumkara
  • Compounds, compositions and methods
    Patent number: 11174262
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: November 16, 2021
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cinzia Maria Francini, Cheng Hu, Colin Philip Leslie, Maksim Osipov, Anantha Sudhakar, Zachary K. Sweeney, Javier De Vicente Fidalgo
  • Compounds, Compositions and Methods
    Publication number: 20210332058
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 28, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cheng Hu, Maksim Osipov, Zachary K. Sweeney, Javier de Vicente Fidalgo, Arun Thottumkara
  • SUBSTITUTED PYRIMIDINES AS LRKK2 INHIBITORS
    Publication number: 20210300914
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Application
    Filed: June 7, 2021
    Publication date: September 30, 2021
    Applicant: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. ESTRADA, Jianwen A. FENG, Joseph P. LYSSIKATOS, Zachary K. SWEENEY, Javier DE VICENTE FIDALGO
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20210292311
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: May 28, 2021
    Publication date: September 23, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Maksim Osipov, Arun Thottumkara
  • Compounds, compositions, and methods
    Patent number: 11111235
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: September 7, 2021
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • Compounds, compositions and methods
    Patent number: 11072618
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: June 7, 2019
    Date of Patent: July 27, 2021
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Cheng Hu, Maksim Osipov, Zachary K. Sweeney, Javier de Vicente Fidalgo, Arun Thottumkara
  • Substituted pyrimidines as LRKK2 inhibitors
    Patent number: 11028080
    Abstract: The present disclosure relates generally to compounds of formula (I) or a pharmaceutically acceptable salt, prodrug, deuterated analog, tautomer, stereoisomer, or mixture of stereoisomers thereof and their use as LRRK2 inhibitors.
    Type: Grant
    Filed: March 10, 2017
    Date of Patent: June 8, 2021
    Assignee: DENALI THERAPEUTICS INC.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20210147435
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 8, 2018
    Publication date: May 20, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Christopher R.H. Hale, Katrina W. Lexa, Maksim Osipov, Travis Remarchuk, Zachary K. Sweeney
  • MODULATORS OF EUKARYOTIC INITIATION FACTOR 2
    Publication number: 20210130308
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
    Type: Application
    Filed: March 22, 2019
    Publication date: May 6, 2021
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Brian M. Fox, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney, Arun Thottumkara
  • Pyrazolo[1,5a]pyrimidine derivatives as IRAK4 modulators
    Patent number: 10988478
    Abstract: Compounds of Formula 0, Formula I, and Formula II and methods of use as Interleukin-1 Receptor Associated Kinase (IRAK4) inhibitors are described herein.
    Type: Grant
    Filed: January 29, 2020
    Date of Patent: April 27, 2021
    Assignee: Genentech, Inc.
    Inventors: Marian C. Bryan, Alberto Gobbi, James Richard Kiefer, Jr., Aleksandr Kolesnikov, Alan G. Olivero, Joy Drobnick, Jun Liang, Naomi Rajapaksa, Chudi Ndubaku, Jianwen Feng
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20210002260
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 13, 2020
    Publication date: January 7, 2021
    Applicant: Denali Therapeutics Inc.
    Inventors: Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20200331900
    Abstract: The present disclosure relates generally to eukaryotic initiation factor 2B modulators, or a pharmaceutically acceptable salt, stereoisomer, mixture of stereoisomers, or prodrug thereof, and methods of making and using thereof.
    Type: Application
    Filed: August 31, 2018
    Publication date: October 22, 2020
    Inventors: Robert A. Craig, II, Javier de Vicente Fidalgo, Anthony A. Estrada, Jianwen A. Feng, Katrina W. Lexa, Maksim Osipov, Zachary K. Sweeney
  • Compounds, Compositions and Methods
    Publication number: 20200317691
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: February 5, 2020
    Publication date: October 8, 2020
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Phillip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
    Patent number: 10709692
    Abstract: The present disclosure relates generally to methods and compositions for preventing or arresting cell death and/or inflammation.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: July 14, 2020
    Assignee: Denali Therapeutics Inc.
    Inventors: Giorgio Bonanomi, Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Carmela Napolitano, Alfonso Pozzan, Anantha Sudhakar, Zachary K. Sweeney, Federica Tonelli, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20200157081
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: May 23, 2018
    Publication date: May 21, 2020
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Javier de Vicente Fidalgo, Zachary K. Sweeney